Neurofilament-light chain (NfL) as a biomarker of response to higher-efficacy disease-modifying therapies

November 22, 2023

Recommend to a Colleague print

 

Includes data on NfL changes after initiation of fingolimod, ofatumumab, ocrelizumab, natalizumab, alemtuzumab and oral cladribine.

11 slides

Download the slide deck

Recommend to a Colleague

Related Posts

• Treatment discontinuation in MS: the DOT-MS trial
  May 5, 2025
• CLINICAL CASES IN MS: A 24 Y.O. WOMAN WITH PARESTHESIAE AND NON-ENHANCING LESIONS
  April 25, 2025
• AAN 2025 – report on fluid biomarkers in MS
  April 22, 2025
• Ofatumumab – new data on efficacy and safety
  April 14, 2025
• AAN DAILY HIGHLIGHTS – WEDNESDAY, APRIL 9, 2025
  April 9, 2025

Go back to home page